TAIPEI, Taiwan, April 12 /Xinhua-PRNewswire/ -- At the 6th Annual China Pharmaceutical and Healthcare Industry Summit at Shanghai in China today, Dr. Ming-Chu Hsu, President & CEO of TaiGen Biotechnology Co., Ltd, delivered a keynote speech on the company's strategic focus, "Building Locally and Expanding Globally". She stressed on the long-term and sustainable R&D core value which TaiGen has built through fully utilizing the particular local resources at a relatively lower cost in China and Taiwan. TaiGen has a deep product pipeline from internal R&D programs and clinical stage products in-licensed from biotech companies in USA. TaiGen's full pipeline, pointed out by Dr. Hsu, has validated such a business model for the emerging biotech industry in Asia.
About TaiGen Biotechnology
TaiGen Biotechnology ( www.taigenbiotech.com ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, diabetic complications and cancer. TaiGen has established a full capacity to conduct new drug research and clinical development in China, Taiwan, USA and other countries. In addition to the clinical development of Nemonoxacin, currently in phase 2, the company has a phase 1-ready drug candidate for treating critical limb ischemia and retinopathy/age-related macular degeneracy, and advanced preclinical candidates for Hepatitis C virus infection and cancer.
Contact Information:
Stephen Ip, Ph.D.
SVP Global Business Development
Tel: +886-2-2790-1861
Fax: +8862-2790-9962
Email: sip@taigenbiotech.com
Address: 7F,138 Shin Ming Rd.,Neihu Dist.,
Taipei,Taiwan 11470,R.O.C.